Regeneron Accounts Payable vs Accumulated Other Comprehensive Income Analysis

REGN Stock  USD 962.49  3.81  0.39%   
Regeneron Pharmaceuticals financial indicator trend analysis is much more than just breaking down Regeneron Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regeneron Pharmaceuticals is a good investment. Please check the relationship between Regeneron Pharmaceuticals Accounts Payable and its Accumulated Other Comprehensive Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Accounts Payable vs Accumulated Other Comprehensive Income

Accounts Payable vs Accumulated Other Comprehensive Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regeneron Pharmaceuticals Accounts Payable account and Accumulated Other Comprehensive Income. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Regeneron Pharmaceuticals' Accounts Payable and Accumulated Other Comprehensive Income is -0.57. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Accumulated Other Comprehensive Income in the same time period over historical financial statements of Regeneron Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Regeneron Pharmaceuticals' Accounts Payable and Accumulated Other Comprehensive Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Regeneron Pharmaceuticals are associated (or correlated) with its Accumulated Other Comprehensive Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accumulated Other Comprehensive Income has no effect on the direction of Accounts Payable i.e., Regeneron Pharmaceuticals' Accounts Payable and Accumulated Other Comprehensive Income go up and down completely randomly.

Correlation Coefficient

-0.57
Relationship DirectionNegative 
Relationship StrengthVery Weak

Accounts Payable

An accounting item on the balance sheet that represents Regeneron Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Regeneron Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Accumulated Other Comprehensive Income

Gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized.
Most indicators from Regeneron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.As of the 28th of March 2024, Selling General Administrative is likely to grow to about 2.7 B. Also, Tax Provision is likely to grow to about 584.1 M
 2021 2022 2023 2024 (projected)
Total Operating Expenses4.7B5.6B7.1B7.4B
Cost Of Revenue2.4B1.6B883.7M927.9M

Regeneron Pharmaceuticals fundamental ratios Correlations

0.971.00.94-0.060.990.970.93-0.240.960.980.150.950.32-0.660.970.980.830.930.940.980.580.990.930.980.58
0.970.960.94-0.030.950.990.84-0.310.980.980.20.950.45-0.660.990.990.730.960.880.990.650.970.830.980.56
1.00.960.93-0.090.990.950.94-0.250.950.960.130.920.28-0.670.950.970.850.910.960.960.550.990.940.970.56
0.940.940.93-0.160.890.930.87-0.150.910.940.310.960.37-0.440.960.930.680.860.830.950.670.970.810.960.78
-0.06-0.03-0.09-0.160.0-0.1-0.010.13-0.14-0.01-0.170.08-0.04-0.490.02-0.090.030.22-0.16-0.08-0.04-0.10.01-0.06-0.4
0.990.950.990.890.00.940.93-0.260.950.960.050.910.27-0.750.950.970.870.930.960.950.530.970.950.960.48
0.970.990.950.93-0.10.940.82-0.30.980.980.230.930.45-0.620.980.990.710.950.880.980.630.950.820.970.54
0.930.840.940.87-0.010.930.82-0.070.80.860.070.880.14-0.620.870.840.90.80.910.860.480.930.980.890.6
-0.24-0.31-0.25-0.150.13-0.26-0.3-0.07-0.39-0.2-0.05-0.06-0.370.26-0.19-0.32-0.4-0.26-0.26-0.220.01-0.22-0.15-0.23-0.01
0.960.980.950.91-0.140.950.980.8-0.390.970.180.890.41-0.630.950.990.730.920.910.970.580.950.820.950.5
0.980.980.960.94-0.010.960.980.86-0.20.970.220.970.33-0.650.990.990.710.960.890.980.620.970.850.970.56
0.150.20.130.31-0.170.050.230.07-0.050.180.220.280.270.370.240.19-0.070.170.050.210.230.2-0.020.160.47
0.950.950.920.960.080.910.930.88-0.060.890.970.280.37-0.590.990.930.670.940.810.960.690.950.830.960.65
0.320.450.280.37-0.040.270.450.14-0.370.410.330.270.37-0.130.420.390.120.430.140.450.690.290.120.430.24
-0.66-0.66-0.67-0.44-0.49-0.75-0.62-0.620.26-0.63-0.650.37-0.59-0.13-0.63-0.65-0.71-0.76-0.66-0.61-0.25-0.6-0.71-0.630.11
0.970.990.950.960.020.950.980.87-0.190.950.990.240.990.42-0.630.970.710.960.860.990.680.970.840.980.61
0.980.990.970.93-0.090.970.990.84-0.320.990.990.190.930.39-0.650.970.750.940.910.980.610.970.850.970.53
0.830.730.850.680.030.870.710.9-0.40.730.71-0.070.670.12-0.710.710.750.710.870.720.280.810.940.770.37
0.930.960.910.860.220.930.950.8-0.260.920.960.170.940.43-0.760.960.940.710.810.940.610.910.810.940.4
0.940.880.960.83-0.160.960.880.91-0.260.910.890.050.810.14-0.660.860.910.870.810.870.360.930.940.880.47
0.980.990.960.95-0.080.950.980.86-0.220.970.980.210.960.45-0.610.990.980.720.940.870.730.970.840.990.59
0.580.650.550.67-0.040.530.630.480.010.580.620.230.690.69-0.250.680.610.280.610.360.730.570.410.670.49
0.990.970.990.97-0.10.970.950.93-0.220.950.970.20.950.29-0.60.970.970.810.910.930.970.570.910.970.65
0.930.830.940.810.010.950.820.98-0.150.820.85-0.020.830.12-0.710.840.850.940.810.940.840.410.910.880.47
0.980.980.970.96-0.060.960.970.89-0.230.950.970.160.960.43-0.630.980.970.770.940.880.990.670.970.880.6
0.580.560.560.78-0.40.480.540.6-0.010.50.560.470.650.240.110.610.530.370.40.470.590.490.650.470.6
Click cells to compare fundamentals

Regeneron Pharmaceuticals Account Relationship Matchups

Regeneron Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets14.8B17.2B25.4B29.2B33.1B34.7B
Total Current Liabilities1.8B2.8B3.5B3.8B3.4B3.6B
Total Stockholder Equity11.1B11.0B18.8B22.7B26.0B27.3B
Property Plant And Equipment Net2.9B3.2B3.5B3.8B4.1B4.4B
Net Debt(903.9M)502M(185.9M)(404.5M)(27.1M)(28.5M)
Retained Earnings7.4B10.9B19.0B23.3B27.3B28.6B
Cash1.6B2.2B2.9B3.1B2.7B2.9B
Non Current Assets Total4.2B4.4B4.9B7.1B13.6B14.3B
Non Currrent Assets Other531.8M328.9M555.2M(4.7B)444.1M466.3M
Cash And Short Term Investments6.5B6.7B12.5B14.3B10.8B11.4B
Net Receivables2.7B4.1B6.0B5.3B5.7B6.0B
Common Stock Shares Outstanding114.6M115.1M112.2M113.5M113.7M75.4M
Liabilities And Stockholders Equity14.8B17.2B25.4B29.2B33.1B34.7B
Non Current Liabilities Total1.9B3.3B3.2B2.7B3.7B3.9B
Other Current Assets959.3M1.2B332.4M933M386.6M203.9M
Other Stockholder Equity3.7B102.9M(173.4M)(404M)(1.2B)(1.1B)
Total Liab3.7B6.1B6.7B6.6B7.1B7.5B
Total Current Assets10.6B12.8B20.5B22.1B19.5B20.5B
Short Long Term Debt Total713.9M2.7B2.7B2.7B2.7B2.8B
Other Current Liab781.1M122.4M1.7B2.0B2.4B2.5B
Accounts Payable418.1M475.5M564M589.2M606.6M636.9M
Property Plant And Equipment Gross2.9B3.2B4.9B5.4B6.1B6.4B
Accumulated Other Comprehensive Income21.1M29.3M(26.2M)(238.8M)(80.9M)(76.9M)
Short Term Investments1.6B1.4B2.8B4.6B8.1B8.5B
Inventory1.4B1.9B2.0B2.4B2.6B2.7B
Other Liab889M635.5M515.3M707.8M814.0M854.7M
Other Assets913.3M2.8B555.2M747.6M859.7M902.7M
Property Plant Equipment2.9B3.2B3.5B3.8B4.3B4.5B
Current Deferred Revenue591.7M577.7M442M547.7M458.9M481.8M
Net Tangible Assets11.1B11.0B18.8B21.7B25.0B26.3B
Retained Earnings Total Equity7.4B10.9B19.0B23.3B26.8B28.1B
Long Term Debt Total713.9M2.0B2.0B2.0B2.3B2.4B
Capital Surpluse4.4B6.7B8.1B9.9B11.4B12.0B
Long Term Investments3.3B3.1B6.8B6.6B5.4B3.3B

Regeneron Pharmaceuticals Investors Sentiment

The influence of Regeneron Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Regeneron. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Regeneron Pharmaceuticals' public news can be used to forecast risks associated with an investment in Regeneron. The trend in average sentiment can be used to explain how an investor holding Regeneron can time the market purely based on public headlines and social activities around Regeneron Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Regeneron Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Regeneron Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Regeneron Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Implied Volatility

    
  25.45  
Regeneron Pharmaceuticals' implied volatility exposes the market's sentiment of Regeneron Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Regeneron Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Regeneron Pharmaceuticals stock will not fluctuate a lot when Regeneron Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regeneron Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regeneron Pharmaceuticals' short interest history, or implied volatility extrapolated from Regeneron Pharmaceuticals options trading.

Currently Active Assets on Macroaxis

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.03)
Earnings Share
34.78
Revenue Per Share
122.935
Quarterly Revenue Growth
0.006
Return On Assets
0.0849
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.